All lobbying filings

RARE DISEASE COMPANY COALITION

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $70,000.00 expenses · posted Jul 16, 2026

Official filing document

Bills named in this filing 3

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 1414
Cameron’s Law
HR 7148
Consolidated Appropriations Act, 2026

Lobbying activity 1

Pharmacy

HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.